They include: Saum Ghodoussipour, M.D., Rutgers Cancer Institute of New Jersey: Dynamic intra-tumor heterogeneity in non-muscle invasive bladder cancer Taylor Goodstein, M.D., Emory University: ...

Introduction of NDV-01, a potentially first-line therapy for high-risk non-muscle invasive bladder cancer (HG-NMIBC), signifies innovation in drug formulation aimed at improving patient outcomes ...